☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Interim Analysis
Sinopharm's COVID-19 Vaccine Demonstrates 79% Efficacy in P-III Study
December 31, 2020
Moderna's mRNA-1273 Demonstrates 94.5% Efficacy in Preventing Symptomatic COVID-19
November 17, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.